The phase III IMpower010 trial reinforced the significant disease-free survival benefit offered by Tecentriq (atezolizumab) for people with stage II-IIIA non-small cell lung cancer whose tumors express PD-L1≥1%.
When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.
